# Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

> **NCT04527991** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 712 (actual)

## Conditions studied

- Locally Advanced or Metastatic Unresectable Urothelial Cancer

## Interventions

- **DRUG:** Sacituzumab Govitecan-hziy
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Vinflunine

## Key facts

- **NCT ID:** NCT04527991
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-13
- **Primary completion:** 2025-07-04
- **Final completion:** 2025-07-04
- **Target enrollment:** 712 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04527991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04527991, "Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04527991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*